Home › Companies › CAPR

Capricor Therapeutics

Market cap $489M 58.1M shares (10-Q, Nov 9, 2026) × $8.41 close Nov 17, 2026

Most recent annual filing: 2026-03-17

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. Deramiocel PDUFA dateNov 22, 2026Deramiocel PDUFA date, Nov 22, 2026, thesis-defining
  2. NS Pharma arbitration corporate updatemid-2027NS Pharma arbitration corporate update, mid-2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

Technology platforms

StealthX

Proprietary exosome-based platform for targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of rare diseases. Development slowed to prioritize Deramiocel pending regulatory clarity.

StealthX · Life Technologies Corporation

CDC-derived exosomes platform technology for therapeutic development; disease focus includes Duchenne muscular dystrophy and other diseases with high unmet medical needs

Capital (as filed)

Cash
$44.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$153M Sep 30, 2026
Operating cash flow
−$35.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$199M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (14)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (14 calls)

Every verdict Biotech Distilled has published on Capricor Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Capricor Therapeutics (CAPR) — Scientific Deep Dive for Deramiocel and the StealthX Exosome Platform Real Phase 3 data and best-in-class safety collide with a re-review that already failed once and a commercial structure the company is suing to escape, stacking too many live binaries to commit capital.
  2. Watch UPDATE: Capricor Therapeutics (CAPR) — A Third Binary Lands on the Calendar An FDA-called AdCom adds a third public failure mode without removing either original binary, and none of the upgrade triggers have been met.
  3. Watch UPDATE: Capricor Therapeutics (CAPR) — Signing a 138-Month Lease Two Weeks Before AdCom Management's 138-month lease signals internal confidence in approval, but the trinary of injunction, AdCom, and PDUFA remains intact and none of the upgrade triggers have been met.
  4. Watch UPDATE: Capricor Therapeutics (CAPR) — The FDA Showed Its Cards, and the Stock Lost Two-Thirds FDA briefing documents contest the governing SAP and the stock has collapsed 66%, but the watch-list stance was built for exactly this risk and the binary has repriced rather than resolved.
  5. Watch UPDATE: Capricor Therapeutics (CAPR) — The Key Secondary Just Lost Its Star LVEF revised to p=0.09 by the company's own hand on AdCom morning, leaving only the PUL primary and safety to carry the bull case, with one of three upgrade triggers now met via Lancet publication.
  6. Watch UPDATE: Capricor Therapeutics (CAPR) — 9-3 Against, and the Stock Falls Below Cash A 9-3 panel vote against effectiveness in DMD cardiomyopathy makes a CRL the modal outcome, but the stock now trades below cash creating asymmetry that speculative capital might find interesting.
  7. Speculative buy speculative UPDATE: Capricor Therapeutics (CAPR) — RA Capital Just Showed Up RA Capital crossing 5% during the briefing-book collapse retires the 'no conviction money' bear-case pillar, and with market cap below cash and a ~$150–200M PRV as optionality, the risk/reward has genuinely shifted.
  8. Speculative buy speculative UPDATE: Capricor Therapeutics (CAPR) — The Cash Cushion Got Thinner Nine Days Before PDUFA Cash fell to $237.9M and burn accelerated, but the upgrade rationale remains intact at a slightly shallower margin with the NS injunction withdrawn to arbitration and commercial readiness throttled.
  9. Speculative buy speculative UPDATE: Capricor Therapeutics (CAPR) — The August 22 Binary Just Got Cancelled FDA agreed to review a BLA amendment with 24-month OLE data for a refined upper-limb indication, converting a near-certain CRL binary into a multi-month process, while Tang Capital at 7.1% further retires the 'no conviction money' bear case.
  10. Speculative buy speculative UPDATE: Capricor Therapeutics (CAPR) — An Activist Kicks the Door In Kaos Capital's activist campaign validates the burn-rate concern and creates pressure to fix it, while the holder base has fully inverted from retail-driven to organized specialist ownership, though the BLA amendment remains the whole ballgame.
  11. Speculative buy speculative UPDATE: Capricor Therapeutics (CAPR) — The New Date Is November 22 FDA formally accepted the major amendment and set November 22 as the new PDUFA, confirming the refined upper-limb indication path, though the lease kill switch now has only 39 days of buffer after the decision date.
  12. Speculative buy speculative UPDATE: Capricor Therapeutics (CAPR) - The Before-and-After Picture 24-month OLE crossover data shows a 76% reduction in arm-function decline in former placebo patients and no fading in early-start patients, passing the durability test the amendment needed, though the evidence remains uncontrolled and the asset premium has widened.
  13. Hold UPDATE: Capricor Therapeutics (CAPR) - The Last Balance Sheet Before the Binary At $8.87 the market cap embeds a ~$317M asset premium well above the PRV value, flipping the asymmetry from favorable to roughly symmetric, making trimming into the binary reasonable for holders while new money has little reason to step in.
  14. Hold UPDATE: Capricor Therapeutics (CAPR) - Tang Capital Walked Out Before the Verdict Tang Capital's full exit by September 30 removes the larger specialist anchor and weakens the downside cushion, reinforcing the case for trimming before November 22 while the evidence base and roughly symmetric risk/reward are unchanged.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)